Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.52 |
| ▸ | STAT3 | P40763 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 4/20 | 0.51 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.51 |
| ▸ | TNF | P01375 | 1/20 | 0.49 |
| ▸ | IL1B | P01584 | 1/20 | 0.49 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.49 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.49 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20913681 | 0.89 | CRBN (0.55) | CRBNSTAT3BRD4RIPK2TNF | |
| SCHEMBL17821424 | 0.89 | CRBN (0.55) | CRBNSTAT3BRD4RIPK2TNF | |
| SCHEMBL25032419 | 0.89 | CRBN (0.55) | CRBNSTAT3BRD4RIPK2TNF | |
| SCHEMBL23772826 | 0.89 | CRBN (0.55) | CRBNSTAT3BRD4RIPK2TNF | |
| SCHEMBL18639838 | 0.89 | CRBN (0.55) | CRBNSTAT3BRD4RIPK2TNF | |
| SCHEMBL25757131 | 0.88 | CRBN (0.56) | CRBNSTAT3BRD4RIPK2TNF | |
| SCHEMBL23765963 | 0.88 | STAT3 (0.56) | CRBNSTAT3BRD4RIPK2TNF | |
| SCHEMBL23766258 | 0.88 | STAT3 (0.56) | CRBNSTAT3BRD4RIPK2TNF | |
| SCHEMBL18639827 | 0.87 | CRBN (0.57) | CRBNSTAT3BRD4TNFIL1B | |
| SCHEMBL24778362 | 0.87 | CRBN (0.57) | CRBNSTAT3BRD4TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376094-A2 | SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE | LES LABORATOIRES SERVIER (FR) | 2024-11-14 | — | — | US | disclosed |
| US-20240182464-A1 | SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE | Les Laboratoirens Serviece (FR) | 2024-06-06 | — | — | US | disclosed |
| EP-4288434-A1 | SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE | Les Laboratoires Servier (FR) | 2023-12-13 | — | — | EP | disclosed |
| US-11319316-B2 | Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof | BIOVENTURES, LLC (US) | 2022-05-03 | — | — | US | disclosed |
| US-11319316-B2 | Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof | BIOVENTURES, LLC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20200331905-A1 | Compounds That Induce Degradation of Anti-Apoptotic BCL-2 Family Proteins and the Uses Thereof | BIOVENTURES, LLC | 2020-10-22 | — | — | US | disclosed |
| US-20200331905-A1 | Compounds That Induce Degradation of Anti-Apoptotic BCL-2 Family Proteins and the Uses Thereof | BIOVENTURES, LLC | 2020-10-22 | — | — | US | disclosed |
| US-10807977-B2 | Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof | BIOVENTURES, LLC (US) | 2020-10-20 | — | — | US | disclosed |
| US-10807977-B2 | Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof | BIOVENTURES, LLC (US) | 2020-10-20 | — | — | US | disclosed |
| WO-2020081880-A1 | COMPOSITIONS TARGETING SENESCENT CELLS AND THE USES THEREOF | BIOVENTURES, LLC (US) | 2020-04-23 | — | — | WO | disclosed |
| US-20190135801-A1 | COMPOUNDS THAT INDUCE DEGRADATION OF ANTI-APOPTOTIC BCL-2 FAMILY PROTEINS AND THE USES THEREOF | BIOVENTURES, LLC | 2019-05-09 | — | — | US | disclosed |
| US-20190135801-A1 | COMPOUNDS THAT INDUCE DEGRADATION OF ANTI-APOPTOTIC BCL-2 FAMILY PROTEINS AND THE USES THEREOF | BIOVENTURES, LLC | 2019-05-09 | — | — | US | disclosed |
| US-20190054097-A1 | COMPOSITIONS TARGETING SENESCENT CELLS AND THE USES THEREOF | BIOVENTURES, LLC | 2019-02-21 | — | — | US | disclosed |
| US-20190054097-A1 | COMPOSITIONS TARGETING SENESCENT CELLS AND THE USES THEREOF | BIOVENTURES, LLC | 2019-02-21 | — | — | US | disclosed |
| WO-2017184995-A1 | COMPOUNDS THAT INDUCE DEGRADATION OF ANTI-APOPTOTIC BCL-2 FAMILY PROTEINS AND THE USES THEREOF | BIOVENTURES, LLC (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017184995-A1 | COMPOUNDS THAT INDUCE DEGRADATION OF ANTI-APOPTOTIC BCL-2 FAMILY PROTEINS AND THE USES THEREOF | BIOVENTURES, LLC (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182464-A1 | SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE | CRBN, XIAP, BCL2L11 | CRBN 1/4885STAT3 364/4885BRD4 927/4885 |
| US-20200331905-A1 | Compounds That Induce Degradation of Anti-Apoptotic BCL-2 Family Proteins and the Uses Thereof | BCL2, BAX, BCL2L1 | CRBN 520/4885STAT3 932/4885BRD4 899/4885 |
| US-20240376094-A2 | SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE | CRBN, XIAP, BCL2L11 | CRBN 1/4885STAT3 364/4885BRD4 927/4885 |
| US-20190135801-A1 | COMPOUNDS THAT INDUCE DEGRADATION OF ANTI-APOPTOTIC BCL-2 FAMILY PROTEINS AND THE USES THEREOF | BCL2, BAX, BCL2L1 | CRBN 520/4885STAT3 932/4885BRD4 899/4885 |
| US-11319316-B2 | Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof | BCL2, BAX, BCL2L1 | CRBN 520/4885STAT3 932/4885BRD4 899/4885 |
| US-10807977-B2 | Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof | BCL2, BAX, BCL2L1 | CRBN 520/4885STAT3 932/4885BRD4 899/4885 |
| US-20190054097-A1 | COMPOSITIONS TARGETING SENESCENT CELLS AND THE USES THEREOF | TP53, MCL1, LIMS1 | CRBN 1187/4885STAT3 754/4885BRD4 2308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.